Introduction {#sec1-1}
============

Colorectal cancer is the third commonest cancer world-wide. Nearly 40% of patients had metastatic disease at presentation.\[[@ref1]\] K-ras oncogene mutational status has been found to be a predictor of response to cetuximab therapy in metastatic colorectal cancer (mCRC) and reported to be present in 35-40% of colorectal cancers.\[[@ref2][@ref3]\] The activity of epidermal growth factor receptor (EGFR) targeting monoclonal antibody cetuximab is limited to patients whose tumors do not harbor mutation at codons 12 and 13 of the K-ras gene.\[[@ref4][@ref5][@ref6][@ref7]\] This observation was confirmed in two large clinical studies: Phase III CRYSTAL study (Cetuximab combined with irinotecan in first-line therapy for mCRC)\[[@ref8]\] and large-scale Phase II OPUS study (Oxaliplatin and Cetuximab in First-Line treatment of mCRC).\[[@ref9]\]

The recent CRYSTAL study updates revealed that the addition of cetuximab to FOLFIRI in patients with K-ras wild-type disease resulted in significant improvement in progression-free survival (PFS), overall survival (OS) and objective response (OR) compared with FOLFIRI alone.\[[@ref10]\] The large Phase II OPUS study also demonstrated that the addition of cetuximab to FOLFOX-4 significantly improved PFS and OR in patients with K-ras wild-type tumors.\[[@ref9]\]

More recently, the pooled analysis of CRYSTAL and OPUS study published in 2012 consolidated the previous finding that the addition of cetuximab to first-line chemotherapy in patients with K-ras wild-type tumors led to a significant increase in OR, reduction in risk of disease progression and risk of death compared with chemotherapy alone.\[[@ref11]\] However, conflicting results was revealed in the Phase III Medical Research Council (MRC) COIN study which confirmed that adding cetuximab to FOLFOX-4 improved response rate but not PFS or even OS in patients with K-ras wild-type tumors.\[[@ref12]\]

Nevertheless, cetuximab has been approved in a number of countries for clinical use in patients with K-ras wild-type mCRC. The typical dose is a weekly schedule while most chemotherapy regimens for mCRC are usually given biweekly or every 3 weeks.\[[@ref13][@ref14]\] The notion of synchronizing the administration of cetuximab and concomitant chemotherapy would definitely simplify treatment administration and reduce its impact on patients' convenience. Pharmacokinetics and pharmacodynamic studies have provided evidence that biweekly administration of cetuximab is not different from weekly schedule.\[[@ref15][@ref16][@ref17]\]

The aim of our study is to investigate the feasibility, efficacy and safety of using biweekly cetuximab with oxaliplatin-based chemotherapy or irinotecan-based chemotherapy as first-line treatment for Chinese patients with K-ras wild-type mCRC.

Materials and Methods {#sec1-2}
=====================

This study was a prospective, single-arm, open-label Phase II trial conducted in a single institution to investigate the efficacy and safety of biweekly cetuximab and chemotherapy as first-line treatment in patients with K-ras wild-type mCRC.

Eligible patients must have metastatic disease with K-ras wild-type status of tumour tissue and confirmed histologically adenocarcinoma of the colon or rectum.

Patients' inclusion and exclusion criteria are shown in [Table 1](#T1){ref-type="table"}.

###### 

Inclusion and exclusion criteria
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The study protocol was approved by the institutional review board of the treating institution and conducted in accordance with the Declaration of Helsinki 2000 as well as the Declaration of Istanbul 2009. All patients provided written informed consent before enrollment into the study.

Procedures {#sec2-1}
----------

Baseline assessments include medical history, physical examination, vital signs, blood taking for hematology with complete blood counts, including differential leucocyte count, clinical biochemistry with liver and renal function tests, magnesium level, tumor marker carcinoembryonic antigen and computed tomography (CT) scan of the abdomen and pelvis.

If confirmed eligible after baseline assessment, patients then received chemotherapy either FOLFOX-4\[[@ref13]\] or FOLFIRI\[[@ref14]\] at preference of patients and physicians combined with biweekly cetuximab. Cetuximab 500 mg/m^2^ was given intravenously over 120 min at the first dose, followed by 60-min infusion in subsequent treatments every 2 weeks. Pre-medication diphenhydramide 50 mg was given 30 min before infusion of cetuximab. 1 h after completion of cetuximab, chemotherapy using FOLFOX-4 (oxaliplatin 85 mg/m^2^ on day 1, folinic acid 200 mg/m^2^ on day 1-2 and 5-fluorouracil 400 mg/m^2^ bolus followed by 22-h continuous infusion of 600 mg/m^2^ on day 1-2) or FOLFIRI (irinotecan 180 mg/m^2^ on day 1, folinic acid 200 mg/m^2^ on day 1-2 and 5-fluorouracil 400 mg/m^2^ bolus followed by 22-h continuous infusion of 600 mg/m^2^ day 1-2) was given. Patients who had no radiological evidence of progression or unacceptable toxicity were treated for a maximum of 12 cycles of chemotherapy. Then they had an option to continue maintenance cetuximab with the same dose and schedule until further progressive disease (PD) or unacceptable toxicity developed.

Physical examinations, vital signs, hematology and biochemistry were performed and monitored at baseline and before each chemotherapy or treatment cycle.

Tumor response was evaluated by CT every four cycles (i.e., 8 weeks) until PD. Tumor assessment was classified as complete response (CR), partial response (PR), stable disease or PD according to Response Evaluation Criteria in Solid Tumors version 1.0.\[[@ref18]\] Primary study endpoint was PFS. Secondary endpoints were overall OR, disease control rate (DCR) and OS. Toxicity was evaluated according to National Cancer Institute Common Terminology Criteria version 3.0.

Statistical analysis {#sec2-2}
--------------------

All data were analyzed with Statistical Package for Social Sciences version 19 by IBM. PFS and OS were analyzed by the Kaplan-Meier method and stratified log-rank test.

Results {#sec1-3}
=======

Between December 2009 and August 2010, a total of 15 Chinese patients were recruited into the study. 10 were male (67%) and the median age was 60 years old (range 41-80) \[[Table 2](#T2){ref-type="table"}\]. The distribution of metastatic sites was: Liver (12; 80%), distant lymph nodes (7; 47%), peritoneum (6; 40%), lung (5; 33%), spleen (1; 7%) and bone (1; 7%). Patients received a median number of 12 cycles (range 2-12) of chemotherapy with cetuximab. Nine patients (60%) received FOLFOX-4 with cetuximab and six patients (40%) received FOLFIRI with cetuximab regimen. Six patients (40%) continued maintenance cetuximab after completion of 12 cycles of chemotherapy with cetuximab. The median number of cycles of maintenance cetuximab was 10 (range from 2 to 18) \[[Table 3](#T3){ref-type="table"}\].

###### 

Patient\'s demographics

![](SAJC-3-175-g002)

###### 

Summary of the number of cycles of chemotherapy and cetuximab
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Duration of median follow-up was 23.7 months. OR was 40%. No patient had CR and six had PR. DCR was 87%. Median PFS counting from starting date of chemotherapy was 7.8 months with 1-year PFS rate 23.3% \[[Figure 1](#F1){ref-type="fig"}\]. Median OS was 17.9 months and 1-year OS was 60% \[[Figure 2](#F2){ref-type="fig"}\].
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The only grade 3-4 toxicity in these 15 patients during the chemotherapy phase was neutropenia (26.7%). Other grade 1-2 toxicities included acneiform rash (93.3%), hand-foot syndrome (73.3%), nausea and vomiting (66.7%), diarrhea (40.0%), peripheral neuropathy (40.0%), liver toxicity (20.0%), thrombocytopenia (13.3%) and infusion reaction (6.7%). Nine patients had their chemotherapy delayed due to neutropenia or thrombocytopenia. In a total of 148 cycles of chemotherapy with cetuximab, 16 cycles were delayed (10.8%) with an average of 7.4 days of delay in the total treatment period.

Six patients had stable disease after 12 cycles of chemotherapy and carried on the maintenance cetuximab. The median PFS (calculated from the start of maintenance therapy until progression or death from any cause) was 6.8 months and the median OS was 17.0 months. The best treatment response achieved before disease progression was stable disease in these six patients. The only grade 3-4 toxicities detected during maintenance treatment was acneiform rash (one patient, 16.7%). There was no infusion reaction or hypomagnesaemia.

There were two serious adverse events (SAE). One patient had perforation of the tumor causing intra-abdominal abscess after two cycles of FOLFOX-4 with cetuximab. He had exploratory laparotomy and it was subsided after intensive intravenous antibiotics. Chemotherapy was stopped and permanently discontinued. Another patient, who had history of hypertension and diabetes mellitus, suffered from thrombosis of the left femoral artery after three cycles of FOLFIRI with cetuximab. Chemotherapy was stopped. He subsequently had femoral artery embolectomy and above-knee amputation. Both SAE were not related to the study medications.

Discussion {#sec1-4}
==========

Monoclonal antibody against EGFR was first tested in animal studies in 1980s. After decades of numerous clinical trials, the first monoclonal antibody was approved in the treatment of mCRC. Examples of anti-EGFR monoclonal antibody include cetuximab and panitumumab, binding to the extra-cellular domain of EGFR, blocking the ligand binding-induced receptor dimerization and subsequent tyrosine kinase activation.\[[@ref19]\] Cetuximab, in particular, is also able to elicit antibody-dependent cellular cytotoxicity against tumor cells.\[[@ref20][@ref21]\] K-ras is a guanosine 5'- triphosphate-binding protein which plays crucial in the downstream signaling cascade of various receptor tyrosine kinase including EGFR. K-ras activating mutation is found in about 40% of colorectal cancer, which leads to the constitutive activation of K-ras protein independent of the upstream regulation, thus conferring a poor response to anti-EGFR monoclonal antibody. Subsequent Phase II and Phase III clinical trials have confirmed the role and efficacy of anti-EGFR monoclonal antibody in K-ras wild-type mCRC.

Cetuximab combined with oxaliplatin or irinotecan-based chemotherapy as first-line treatment for K-ras wild-type mCRC has been reported to improve OR, PFS and even OS in different studies,\[[@ref8][@ref9][@ref10][@ref11]\] although the recent MRC COIN study did not reproduce such benefits.\[[@ref12]\] Cetuximab was generally given in weekly dose (400 mg/m^2^ as induction in the first dose followed by weekly dose with 250 mg/m^2^ ) while most chemotherapy regimens for colorectal cancers are given every 2 weeks. It would be reasonable and desirable to synchronize the administration of cetuximab and chemotherapy to improve treatment complexity. Pharmacokinetics and pharmacodynamic studies has proven that biweekly administration of cetuximab has no observable difference when given weekly.\[[@ref15][@ref16][@ref17]\]

Our study demonstrated the feasibility, efficacy and safety of combination of biweekly cetuximab with chemotherapy was comparable with weekly cetuximab as first-line treatment for patients with K-ras wild type mCRC.

In our study, OR was 40% and DCR was 84%, which was similar to the histological data (around 81% as in CRYSTAL study). The median PFS and OS were also similar to those reported in CRYSTAL (median PFS: 9.9 months; median OS: 23.5 months)\[[@ref10]\] and OPUS study (median PFS: 8.3 months; median OS: 22.8 months).\[[@ref9]\]

Biweekly cetuximab with combination of oxaliplatin or irinotecan-based chemotherapy was well tolerated with just 13.3% patients suffering from grade ≥3 neutropenia. Other side effects included mild grade 1-2 gastrointestinal toxicities, hand-foot syndrome, acneiform rash. There were no severe adverse events related to the study medications occurred in our patients. The toxicity profile was in line with the reported incidence in those large scale studies: CRYSTAL,\[[@ref10]\] OPUS\[[@ref9]\] and COIN\[[@ref12]\] study, reflecting that this biweekly regimen is safe when used in combination with chemotherapy.

In our trial, there was a subgroup of six patients having maintenance cetuximab after completion of 12 cycles of chemotherapy. The median number of cycles of maintenance cetuximab was 10 (range from 2 to 18). The median PFS was 6.8 months after the commencement of maintenance treatment and the median OS was 17.0 months. It was well tolerated with only one patient having acneiform rash. Despite the small sample size without any meaningful conclusion, use of maintenance cetuximab in patients with stable disease after first-line chemotherapy was demonstrated to be safe and it is worthwhile to be further elucidated in future studies.

There were several limitations in this study. First, patients enrolled in this study could choose either oxaliplatin or irinotecan-based chemotherapy. This made the efficacy and toxicity profile difficult for comparison. Second, the sample size was too small with a total of only 15 patients and just six patients carried on the maintenance cetuximab. A prospective randomized-controlled trial is definitely warranted to investigate if maintenance therapy with cetuximab offers longer PFS or not.

Conclusion {#sec1-5}
==========

Biweekly cetuximab with oxaliplatin or irinotecan-based chemotherapy in Chinese patients with K-ras wild-type mCRC was safe and feasible and has similar efficacy to the weekly regimen.
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